CN Patent

CN118440940A — 用于抑制ldha表达的方法和组合物

Assigned to Novo Nordisk Health Care AG · Expires 2024-08-06 · 2y expired

What this patent protects

本发明涉及用于抑制LDHA表达的方法和组合物。本公开内容涉及可用于降低LDHA表达、特别是肝细胞中的LDHA表达的寡核苷酸、组合物和方法。

USPTO Abstract

本发明涉及用于抑制LDHA表达的方法和组合物。本公开内容涉及可用于降低LDHA表达、特别是肝细胞中的LDHA表达的寡核苷酸、组合物和方法。

Drugs covered by this patent

nedosiran-sodium (NEDOSIRAN SODIUM)

Patent Metadata

Patent number: CN118440940A
Jurisdiction: CN
Classification: —
Expires: 2024-08-06
Drug substance claim: No
Drug product claim: No
Assignee: Novo Nordisk Health Care AG
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.